Xencor, Inc.
(NASDAQ : XNCR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.43%688.872.6%$679.29m
MRNAModerna, Inc. 0.15%118.250.0%$616.94m
AMGNAmgen, Inc. -1.32%225.401.4%$605.62m
BIIBBiogen, Inc. 1.03%267.001.8%$554.62m
GILDGilead Sciences, Inc. -2.19%61.691.0%$514.54m
VRTXVertex Pharmaceuticals, Inc. -1.11%289.541.9%$401.56m
ILMNIllumina, Inc. -1.56%190.793.2%$338.76m
SNSSSunesis Pharmaceuticals, Inc. 4.40%4.270.7%$298.49m
SAVACassava Sciences, Inc. -2.90%41.820.0%$189.63m
BNTXBioNTech SE 0.96%134.880.0%$112.19m
NVAXNovavax, Inc. -1.99%18.2075.6%$84.03m
BMRNBioMarin Pharmaceutical, Inc. -0.34%84.774.2%$82.56m
NRBONeuroBo Pharmaceuticals, Inc. 9.35%13.690.0%$78.90m
PRTAProthena Corp. Plc 1.95%60.6313.8%$78.20m
CRSPCRISPR Therapeutics AG 1.33%65.350.6%$76.10m

Company Profile

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.